Myeloid but not hepatocytic CD38 is a key driver for hepatic ischemia/reperfusion injury.
Saved in:
| Title: | Myeloid but not hepatocytic CD38 is a key driver for hepatic ischemia/reperfusion injury. |
|---|---|
| Authors: | Zhao QH; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China.; School of Life Science, Nanchang University, Nanchang 330031, China., Zhang YT; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China.; School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang 330031, China., Wen K; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China.; School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang 330031, China., Ding Q; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China., Chen ZY; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China.; School of Life Science, Nanchang University, Nanchang 330031, China., Tula D; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China., Li JH; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China., Zhou J; Department of Gynecology and Obstetrics, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China., Xiao YF; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China., Guan XH; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China., Deng KY; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China. dky@ncu.edu.cn.; School of Life Science, Nanchang University, Nanchang 330031, China. dky@ncu.edu.cn.; School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang 330031, China. dky@ncu.edu.cn., Wang LF; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China. wlfang1985@ncu.edu.cn., Xin HB; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China. xinhb@ncu.edu.cn.; School of Life Science, Nanchang University, Nanchang 330031, China. xinhb@ncu.edu.cn.; School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang 330031, China. xinhb@ncu.edu.cn. |
| Source: | Signal transduction and targeted therapy [Signal Transduct Target Ther] 2025 May 09; Vol. 10 (1), pp. 150. Date of Electronic Publication: 2025 May 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
